arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Lantern Pharma Inc.

LTRN
$1.38 ▲ +0.02 (+1.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lantern Pharma Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $17.1M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 86.1%
FCF / Share $-0.24
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-3.33M
↑ +26.6%
FCF / Share Free cash flow per share
$-0.24
↑ +29.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters